Funduscein-25
(Fluorescein Sodium)Phase 2Small molecule
Funduscein-25 is one of 125 small molecule programs targeting Melanoma. It is currently in Phase 2.
3
Indications
11
Total Trials
3
Active Trials
124
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Mekinist
NovartisPhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Cotellic
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intraoperative2 trials
Melanoma2 trials
Age1 trial
Vestibular schwannoma1 trial
3 more indications
Ovarian Cancer1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
FUNDUSCEIN-25
NDA NDA017869
Mar 28, 2006
FLUORESCITE
NDA NDA021980
Aug 8, 2008
AK-FLUOR 10%
NDA NDA022186
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluorescein Sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]